52 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Lilly (LLY) Signs New Immunology Deal With Private Biotech http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-ZC-FT-365638 Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336 Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
United Therapeutics Discontinues PAH Drug After Study Fails http://www.zacks.com/stock/news/373203/united-therapeutics-discontinues-pah-drug-after-study-fails?cid=CS-ZC-FT-373203 Apr 09, 2019 - United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-ZC-FT-376965 Apr 10, 2019 - Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-403595 Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-405274 Apr 28, 2019 - So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y http://www.zacks.com/stock/news/405929/incyte-incy-q1-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-405929 Apr 30, 2019 - While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
3 Tech Stocks for Growth Investors to Buy Right Now http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-406067 Apr 30, 2019 - Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/406364/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-406364 May 01, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Pages: 123456

Page 1>